ClinicalTrials.gov
public full text
Public Domain
Study of CPI-200 in Patients With Advanced Tumors
This is a prospective, open-label, single arm, non-randomized study of CPI-200 in patients with advanced tumors. CPI-200 is administered via intravenous infusion using an accelerated titration method followed by a conventional 3 + 3 study design to identify the maximum tolerated dose (MTD)
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors#966715
- Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT#873013
- A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors#1138844
- CP-609,754 in Treating Patients With Advanced Solid Tumors#869888
- A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies#1074954
Record · ID 836656
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive